1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.36 (-0.8%) to $43.78 on light volume. Thus far, 2.1 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.7 million shares. The stock has ranged in price between $43.69-$44.07 after having opened the day at $43.96 as compared to the previous trading day's close of $44.14. Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $71.8 billion and is part of the health care sector. Shares are up 35.4% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold. TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).